转移性去势抵抗性前列腺癌患者接受[¹⁷⁷Lu]Lu-PSMA I&T治疗后的纵向肾功能变化
结果显示eGFR平均每月下降0.85 mL/min/1.73 m²(95%CI −1.30至−0.40;p<0.001),16例(15%)出现临床显著肾功能下降,基线肾脏脆弱性影响绝对eGFR水平但不改变下降速率,未检测到明确剂量-反应关系。
要点
- 治疗后eGFR平均每月下降0.85 mL/min/1.73 m²(95%CI −1.30至−0.40;p<0.001)。
- 16例(15%)出现临床显著肾功能下降(eGFR较基线降低≥25%),多发生于治疗起始后第一年内。
- 基线肾脏脆弱性(RRI每增加1单位)与绝对eGFR降低6.76 mL/min/1.73 m²独立相关(p<0.001),但不改变下降速率。
核心结论
- 在接受[¹⁷⁷Lu]Lu-PSMA I&T治疗的mCRPC回顾性队列中观察到肾功能随时间可测量地下降,但观察性设计无法将因果归因于放射性配体治疗。
- 临床显著肾功能恶化相对不常见,基线肾脏脆弱性影响整体肾脏储备但不影响下降速率,在给药活度范围内未检测到明确剂量-反应关系。
研究设计与样本
- 纵向肾功能分析纳入具有基线和治疗后eGFR测量值的患者,eGFR采用2021 CKD-EPI肌酐方程(免种族版)计算。
- 采用随机截距和斜率的线性混合效应模型对eGFR随时间变化建模,固定效应包括自首次治疗的时间、估计累积肾脏吸收剂量(基于人群转换因子,无患者特异性剂量测定)和预设肾脏风险指数(RRI,涵盖基线慢性肾病、高血压和糖尿病)。
- 补充分析包括分段模型重建治疗前轨迹、限制12个月分析和非线性检验;临床显著肾功能下降定义为eGFR较基线降低≥25%,采用时间-事件分析评估。
主要发现
- 共纳入105例患者,贡献238次治疗后eGFR测量值,随访长达48个月。
- 肾功能随时间下降,估计平均每月降低0.85 mL/min/1.73 m²(95%CI −1.30至−0.40;p<0.001)。
- 基线肾脏脆弱性与较低绝对eGFR值独立相关(RRI每单位−6.76 mL/min/1.73 m²;p<0.001),但不改变下降速率。
- 在给药活度范围内并使用人群剂量估计,未检测到明确剂量-反应关系。
- 重建的治疗前轨迹显示治疗前肾功能稳定(β=+0.06 mL/min/月;p=0.30),而治疗后eGFR显著下降(β=−0.60 mL/min/月;p<0.001);限制12个月分析显示相似斜率,无非线性证据。
关键数值与推荐
- 临床显著肾功能下降定义为eGFR较基线降低≥25%。
- eGFR计算采用2021 CKD-EPI肌酐方程(免种族版)。
- 预设肾脏风险指数(RRI)涵盖基线慢性肾病、高血压和糖尿病。
临床怎么用
- 研究结果支持在PSMA靶向放射性配体治疗扩展至更早期疾病设置时进行基线肾功能评估和纵向监测。
- 基线肾脏脆弱性影响整体肾脏储备但不改变下降速率,提示基线肾功能评估有助于识别储备较低的患者。
局限性
- 观察性设计无法将肾功能下降因果归因于放射性配体治疗。
- 使用基于人群转换因子的估计累积肾脏吸收剂量,缺乏患者特异性剂量测定。
- 研究的给药活度范围较窄,剂量-反应关系结果需在此背景下解读。
- 将结果外推至更早期治疗设置应视为假设生成性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The kidneys are recognised organs at risk during prostate-specific membrane antigen (PSMA)–targeted radioligand therapy. While clinically overt nephrotoxicity appears uncommon in late-line metastatic castration-resistant prostate cancer (mCRPC), the longitudinal trajectory of renal function following [¹⁷⁷Lu]Lu-PSMA I&T remains incompletely characterised. We aimed to quantify longitudinal changes in renal function in a treated mCRPC cohort and explore clinical factors associated with renal decline. METHODS: This retrospective cohort study included patients with mCRPC treated with [¹⁷⁷Lu]Lu-PSMA I&T between November 2018 and July 2024. Longitudinal renal analyses were performed in patients with baseline and post-treatment estimated glomerular filtration rate (eGFR) measurements, calculated using the 2021 CKD-EPI creatinine equation (race-free version). Changes in eGFR over time were modelled using linear mixed-effects models with random intercepts and slopes. Fixed effects included time since first treatment, estimated cumulative renal absorbed dose (derived from a population-based conversion factor in the absence of patient-specific dosimetry), and a predefined Renal Risk Index (RRI) capturing baseline chronic kidney disease, hypertension, and diabetes mellitus. Additional analyses examined reconstructed pre-treatment trajectories using piecewise modelling, restricted 12-month analyses, and non-linearity testing. Clinically significant renal decline was defined as a ≥ 25% reduction in eGFR from baseline and evaluated using time-to-event analyses. RESULTS: A total of 105 patients were included, contributing 238 post-treatment eGFR measurements over follow-up of up to 48 months. Renal function declined over time with an estimated mean decrease of 0.85 mL/min/1.73 m² per month (95% CI − 1.30 to − 0.40; p < 0.001). Baseline renal vulnerability was independently associated with lower absolute eGFR values (− 6.76 mL/min/1.73 m² per RRI unit; p < 0.001) but did not modify the rate of decline. Within the administered activity range and using population-based dose estimates, no clear dose–response relationship was detected; this finding should be interpreted in the context of the narrow activity range studied and the absence of patient-specific dosimetry. Reconstructed pre-treatment trajectories demonstrated stable renal function prior to therapy (β = +0.06 mL/min/month; p = 0.30), whereas post-treatment eGFR declined significantly (β = −0.60 mL/min/month; p < 0.001). Restricted analyses limited to the first 12 months showed similar slopes, with no evidence of non-linearity. Clinically significant renal decline occurred in 16 patients (15%), most frequently within the first year following treatment initiation. CONCLUSION: In this retrospective mCRPC cohort treated with [¹⁷⁷Lu]Lu-PSMA I&T, a measurable decline in renal function was observed over time, although the observational design precludes causal attribution to radioligand therapy. Clinically significant renal deterioration remained relatively uncommon. Baseline renal vulnerability influenced overall renal reserve but not the rate of decline, and no clear dose–response relationship was detected within the administered activity range. Extrapolation of these findings to earlier-line settings should be considered hypothesis-generating. These findings support baseline renal assessment and longitudinal monitoring as PSMA-targeted radioligand therapy expands to earlier disease settings.
引用
- Cockcroft M, Ferguson T, Meehan K, et al. Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42009764. doi:10.1007/s00259-026-07893-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。